Wednesday, October 4, 2023
Clinical Advances in
The non-vitamin K antagonist oral anticoagulants (NOACs) have the potential to change the way thromboembolic disorders are treated. The Anticoagulation Management section of this site will highlight clinical data updates in settings of atrial fibrillation and venous thromboembolism where the NOACs are now widely used and discuss application of the latest data in patient care.
NOACs are also being investigated in other disorders, including coronary and peripheral artery disease (CAD/PAD), heart failure, and others. The Vascular Protection section of the site will explore the emerging clinical data for NOACs and discuss new paradigms in thrombotic protection and potential implications for clinical care.
View programs for: Anticoagulation Management Vascular Protection
Supported by
Bayer AG
Steering Committee Chair
Professor of Cardiology
University of Edinburgh
Edinburgh, United Kingdom
Professor
St. George's University of London
London, United Kingdom
Professor
University of Connecticut
Storrs, Connecticut, United States
Professor of Internal Medicine and Vascular Disease
H�pital Saint-Louis, AP-HP
Paris University France
McGill University
Montreal, Quebec, Canada
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Sondra and Stephen Hardis Chair in Oncology Research
Vice Chair (Clinical Services)
Director
GI Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, United States
Assistant Professor of Medicine
Harvard Medical School
Director of General Cardiology
Cardiovascular Division
TIMI Study Group
Brigham and Women's Hospital
Boston, Massachusetts, United States
Professor
University of Leuven
Leuven, Belgium
Steering Committee Chair
Professor of Cardiology
University of Edinburgh
Edinburgh, United Kingdom
Professor
Head of Department of Cardiology
Dupuytren University Hospital
Limoges, France
Professor of Medicine
Harvard Medical School
Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Boston, Massachusetts, United States
Professor
McMaster University
Hamilton, Ontario, Canada
Professor of Medicine
Duke University Medical Center
Durham, North Carolina, United States
Professor of Medicine
University of Alberta in Edmonton
Director of Cardiac Catheterization and Interventional Cardiology
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada
PAD is under-recognized and is associated with a high burden of disease and complications. Review the latest information, including guideline recommendations for the treatment of PAD.
Download
Despite optimal therapy, patients with prior ischemic events and perceived stable disease remain at risk for future vascular events. Review risk factors and current and future antithrombotic considerations for CAD and PAD.
Download
Review the global burden of thrombosis, strategies for prevention, and the role of antithrombotics in peripheral artery disease, venous thromboembolism, and heart failure.
Download
Stroke Prevention in Atrial Fibrillation
Download
Steering Committee Chair
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Janssen Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Sanofi; Verseon Corporation
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Janssen Pharmaceuticals
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Janssen Pharmaceuticals
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company/Pfizer Inc.; Daiichi Sankyo, Inc.
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Daiichi Sankyo, Inc.
Received grants for clinical research from: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company/Pfizer Inc.; Daiichi Sankyo, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Bayer AG; Janssen Pharmaceuticals, Inc.
Received grants for clinical research from: Bayer AG; Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Bayer; Leo Pharma
Received grants for clinical research from: Aspen Pharmacare; Leo Pharma; Pfizer
Steering Committee Member
He has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AngioDynamics; Bayer HealthCare; Halozyme Therapeutics; Janssen Pharmaceuticals; Medtronic, Inc.; Pharmacyclics; PharmaCyte; Seattle Genetics, Inc.
Received grants for clinical research from: Amgen Inc.; Array; Bristol-Myers Squibb Company; Leap
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Anthos; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals; MedImmune Inc.; Pfizer Inc.; Portola Pharmaceuticals
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; MedImmune Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc; Portola Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Pfizer Inc
Received grants for clinical research from: Bayer; Bristol-Myers Squibb Company; Pfizer Inc
Steering Committee Chair
Disclosures: As listed above.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bayer AG; Novo Nordisk; Sanofi
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company/Pfizer Inc.; Novartis Pharmaceuticals Corporation
Steering Committee Member
Has disclosed the following relevant financial relationships:
Received grants for clinical research from: Abbott Laboratories; Afimmune; Amarin Corporation plc; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cardax; Chiesi Pharmaceuticals, Inc.; CSL Behring; Eisai Inc.; Ethicon, Inc.; Ferring Pharmaceuticals; Forest Laboratories, Inc.; Fractyl; Idorsia; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Pfizer Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Synatic; The Medicines Company
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Sanofi; SERVIER
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Sanofi
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Janssen Pharmaceuticals; Mytonomy; Procyrion, Inc.
Received grants for clinical research from: Bayer HealthCare; Janssen Pharmaceuticals; Medtronic, Inc.
Steering Committee Member
Has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company/Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Sanofi
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bayer HealthCare